title: Reply to G. Spitzer and M.A. Socinski.
authors.affiliation: Princess Margaret Cancer Centre/University Health Network, Toronto, Canada.
authors.forename: Alona
authors.initials: A
authors.lastname: Zer
authors.affiliation: Princess Margaret Cancer Centre/University Health Network, Toronto, Canada Natasha.Leighl@uhn.ca.
authors.forename: Natasha B
authors.initials: NB
authors.lastname: Leighl
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000188:drug therapy*; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D008297:Male; D010166:Palliative Care / Q000379:methods*; D011799:Quinazolines / Q000627:therapeutic use*; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D011799:Quinazolines; D043823:Taxoids